A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes (SELENE-Asia)
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight Related Comorbidity With or Without Type 2 Diabetes Mellitus (SELENE-Asia)
This study will evaluate the efficacy and safety of AZD6234 compared with placebo in adults who are overweight or obese, with or without type 2 diabetes mellitus.
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 3
Контакты и местонахождение
Контакты исследования
- Имя: AstraZeneca Clinical Study Information Center
- Номер телефона: 1-877-240-9479
- Электронная почта: information.center@astrazeneca.com
Места учебы
-
-
-
Ansārinagar, Индия, 110 029
- Research Site
-
Calicut, Индия, 673008
- Research Site
-
Kolkata, Индия, 700014
- Research Site
-
Ludhiana, Индия, 141001
- Research Site
-
Meerut, Индия, 250005
- Research Site
-
Surat, Индия, 395002
- Research Site
-
-
-
-
-
Beijing, Китай, 100029
- Research Site
-
Bozhou, Китай, 236000
- Research Site
-
Cangzhou, Китай, 061002
- Research Site
-
Changzhou, Китай, 213004
- Research Site
-
Chongqing, Китай, 402260
- Research Site
-
Daqing, Китай, 163316
- Research Site
-
Ganzhou, Китай, 341099
- Research Site
-
Guangzhou, Китай, 510150
- Research Site
-
Guangzhou, Китай, 510800
- Research Site
-
Jiaxing, Китай, 314001
- Research Site
-
Jinan, Китай, 250031
- Research Site
-
Jinan, Китай, 250013
- Research Site
-
Liuzhou, Китай, 545005
- Research Site
-
Luoyang, Китай, 471003
- Research Site
-
Luzhou, Китай, 646000
- Research Site
-
Sanya, Китай, 572000
- Research Site
-
Shanghai, Китай, 200031
- Research Site
-
Shanghai, Китай, 310000
- Research Site
-
Shanghai, Китай, 201700
- Research Site
-
Shenyang, Китай, 110016
- Research Site
-
Shenyang, Китай, 110023
- Research Site
-
Shiyan, Китай, 442099
- Research Site
-
Suzhou, Китай, 215004
- Research Site
-
Wuhan, Китай, 430060
- Research Site
-
Xi'an, Китай, 710068
- Research Site
-
Xuancheng, Китай, 242000
- Research Site
-
Yuncheng, Китай, 044099
- Research Site
-
Zhengzhou, Китай, 450007
- Research Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Aged 18 years or older at the time of signing informed consent.
- Body mass index:
- at least 28 kg/m²; or
- at least 24 kg/m² and less than 28 kg/m² with at least one protocol-defined weight-related comorbidity, including type 2 diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, knee osteoarthritis, or stress urinary incontinence.
- Stable body weight (≤ 5% body weight change) for at least 3 months prior to Randomisation.
- Participants with type 2 diabetes mellitus must:
- have been diagnosed at least 6 months before informed consent;
- have HbA1c between 6.0% and 10.0% at Screening; and
- be managed with diet and exercise alone or with a stable dose of 1 to 3 oral glucose-lowering medications for at least 3 months before Screening.
- At least one previous self-reported unsuccessful attempt to lose body weight.
- Participants of childbearing potential must comply with protocol-defined highly effective contraception requirements and have negative pregnancy tests at Screening and Randomisation.
- Able to provide signed informed consent.
Exclusion Criteria:
- Obesity primarily caused by another endocrine disorder.
- Severe heart failure, defined as New York Heart Association Class IV, or hospitalisation for heart failure within 3 months before Screening.
- Type 1 diabetes mellitus or ketoacidosis or hyperosmolar coma/state within 3 months before Screening.
- Clinically significant gastric-emptying abnormality requiring treatment.
- Significant inflammatory bowel disease or another severe disease or prior surgery affecting the upper gastrointestinal tract.
- Cardiovascular event, percutaneous coronary intervention, or coronary artery bypass graft within 3 months before Screening.
- Previous or planned surgical treatment for obesity.
- Uncontrolled hypothyroidism or hyperthyroidism.
- Significant hepatobiliary disease, including protocol-defined elevations in alanine aminotransferase, aspartate aminotransferase, or total bilirubin.
- Neoplastic disease within 5 years before Screening, except as otherwise permitted by the protocol.
- Clinically important disease or disorder that may place the participant at risk or interfere with study participation.
- Known or suspected drug abuse or alcohol abuse.
- Planned elective surgery requiring discontinuation of study intervention for more than 6 weeks.
- Weight-management treatment within 3 months before Randomisation.
- Treatment with a glucagon-like peptide-1 receptor agonist or another glucagon-like peptide-1-containing medication within 3 months before Randomisation.
- Treatment with a marketed or investigational amylin-based compound within 3 months before Randomisation.
- Use of insulin therapy for type 2 diabetes mellitus.
- Long-term systemic glucocorticoid treatment lasting more than 14 days or use of central nervous system stimulants.
- Concomitant medication that may increase risk, affect study results, or interfere with study participation.
- Unstable major depressive disorder or Patient Health Questionnaire-9 score of 15 or higher.
- History of psychosis or active symptomatic bipolar disorder.
- Active suicidal ideation corresponding to Category 4 or 5 on the Columbia-Suicide Severity Rating Scale, or history of a suicide attempt.
- Participation in another clinical study within 30 days before Screening.
- Known hypersensitivity to AZD6234.
- Involvement in the planning and/or conduct of the study.
- Unlikely or unable to comply with study procedures, restrictions, or requirements.
- Previous randomisation in the present study.
- Currently pregnant or breastfeeding.
- Any other condition that, in the Investigator's judgement, makes participation inappropriate.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Тройной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: AZD6234 Higher Target-Dose
Participants will receive AZD6234 with dose titration to the higher target dose, followed by a safety follow-up period. |
administered once weekly. |
|
Экспериментальный: AZD6234 Lower Target-Dose
Participants will receive AZD6234 with dose titration to the lower target dose, followed by a safety follow-up period. |
administered once weekly. |
|
Плацебо Компаратор: Placebo
Participants will receive matching placebo with dose titration according to the protocol, followed by a safety follow-up period. |
Matching placebo administered once weekly. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percent change in body weight from baseline at Week 64
Временное ограничение: up to 64 weeks
|
To evaluate the effect of AZD6234 as compared to placebo in percent body weight change from baseline of treatment. |
up to 64 weeks
|
|
Number of participants achieving at Least a 5% Reduction in Body Weight From Baseline at Week 64
Временное ограничение: up to 64 weeks
|
To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5% from baseline of treatment. |
up to 64 weeks
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of participants achieving at Least a 10% Reduction in Body Weight From Baseline at Week 64
Временное ограничение: up to 64 weeks
|
To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 10% from baseline of treatment. |
up to 64 weeks
|
|
Change in waist circumference from baseline
Временное ограничение: up to 64 weeks
|
To evaluate the effect of AZD6234 as compared to placebo in waist circumference change from baseline of treatment. |
up to 64 weeks
|
|
Absolute change in weight from baseline
Временное ограничение: up to 64 weeks
|
To evaluate the effect of AZD6234 as compared to placebo on absolute change in weight from baseline of treatment. |
up to 64 weeks
|
|
Percent change in triglycerides from baseline
Временное ограничение: up to 64 weeks
|
To evaluate the effect of AZD6234 as compared to placebo on triglycerides percent change from baseline of treatment. |
up to 64 weeks
|
|
Change in systolic BP from baseline
Временное ограничение: up to 64 weeks
|
To evaluate the effect of AZD6234 as compared to placebo on systolic BP change from baseline of treatment. |
up to 64 weeks
|
|
Number of Participants With Adverse Events
Временное ограничение: From first administration through Week 64 and the 4-week safety follow-up
|
Number of participants with prespecified adverse event categories. |
From first administration through Week 64 and the 4-week safety follow-up
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- D8750C00019
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Сроки обмена IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Критерии совместного доступа к IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .